Results 71 to 80 of about 28,899 (216)
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri +20 more
wiley +1 more source
Costs of Parkinson's Disease and Antiparkinsonian Pharmacotherapy: An Italian Cohort Study [PDF]
Objective: Antiparkinsonian pharmacotherapy is costly and the determinants of drug costs in Parkinson's disease (PD) have been poorly investigated. The objective of this study was to investigate the costs of PD and antiparkinsonian drugs in an Italian ...
Balzer-Geldsetzer, Monika +10 more
core +1 more source
Management of rapid eye movement sleep behavior disorder in patients with Parkinson's disease [PDF]
Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of
Jeffries, Michael
core +1 more source
Canine respiratory coronavirus employs caveolin-1-mediated pathway for internalization to HRT-18G cells [PDF]
Canine respiratory coronavirus (CRCoV), identified in 2003, is a member of the Coronaviridae family. The virus is a betacoronavirus and a close relative of human coronavirus OC43 and bovine coronavirus.
A Milewska +75 more
core +8 more sources
Amantadine for dyskinesias in Parkinson's disease: a randomized controlled trial. [PDF]
BACKGROUND: Dyskinesias are some of the major motor complications that impair quality of life for patients with Parkinson's disease. The purpose of the present study was to investigate the efficacy of amantadine in Parkinson's disease patients suffering ...
Hideyuki Sawada +8 more
doaj +1 more source
What Is the Best Antiviral Agent for Influenza Infection? [PDF]
Four antiviral agents have been approved by the U.S. Food and Drug Administration for the treatment of influenza infection: amantadine (Symmetrel), oseltamivir (Tamiflu), rimantadine (Flumadine), and zanamivir (Relenza).
Fagan, Heather Bittner +1 more
core
Transport of six tyrosine kinase inhibitors: active or passive ? [PDF]
Transport of erlotinib, gefitinib, sorafenib, sunitinib, dasatinib and crizotinib can be active or passive, which was studied by measuring uptake at low (4 °C; passive) and normal temperature (37 °C; active and passive) and by the use of specific organic
J. Honeywell, Richard +3 more
core +6 more sources
Abstract Background Microscopic colitis (MC) typically presents with chronic, non‐bloody watery diarrhea. Diagnosis requires endoscopy with colonic mucosal biopsies. The etiology is multifactorial, with several medications implicated, although only a few cases have been attributed to oral levodopa/dopa‐decarboxylase inhibitor (LDDCI) therapy.
Romana Hintner +10 more
wiley +1 more source
Amantadine for Traumatic Brain Injury—Supporting Evidence and Mode of Action
Traumatic brain injury (TBI) is an important global clinical issue, requiring not only prevention but also effective treatment. Following TBI, diverse parallel and intertwined pathological mechanisms affecting biochemical, neurochemical, and inflammatory
Andrzej Dekundy +4 more
doaj +1 more source
Background Persisting coma is a common complication in (neuro)intensive care in neurological disease such as acute ischemic stroke, intracerebral hemorrhage or subarachnoid hemorrhage. Amantadine acts as a nicotinic receptor antagonist, dopamine receptor
Anna Hofmann +16 more
doaj +1 more source

